Dose and switching data as signatures for postmarketing ‘learning’

• In: Post-Marketing innovation in Drug Development (SIG Pharmacoeconomics/Pharmacoepidemiology and Industrial Pharmacy Section) on Tuesday, 7 September 2004, 14:00-17:00
• At: New Orleans (USA) (2004)
• Type: Presentation
• By: LEUFKENS, Hubert (Utrecht Institute Pharm Sci (UIPS), Pharmacoepidemiology and Pharmacotherapy, Utrecht, Netherlands)
• Abstract:

  Once a drug has been approved for marketing the ‘experiment’ of prescribing and actual usage of the medicine under normal clinical conditions starts. Drug development is a continuum ranging from fundamental, preclinical, clinical and postmarketing ‘learning’. The choice of the drug, the dose regimen and the duration of use are determined by a

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login